Introduction Risankizumab is a humanized monoclonal antibody that selectively inhibits the p19 subunit of interleukin-23 (IL-23), a key driver in the inflammatory cascade associated with ulcerative colitis (UC). This synopsis summarizes pivotal findings from two global, phase 3 randomized clinical trials—INSPIRE substudy 2 (induction) and COMMAND s
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Single-incision Laparoscopy for Gastrostomy
407 Reached2 Comments1 Likes
Intestinal Obstruction and Ileocolic Fistula due to Gossypiboma
861 Reached30 Comments15 Likes
Male Complaining of Bilateral Knee Pain and Gait Disturbance
840 Reached5 Comments1 Likes